ArticleClinical and experimental medicine2026
SIRT1-mediated FABP4 destabilization attenuates fibrosis and ferroptosis in non-alcoholic fatty liver disease.
Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThis study aims to unveil the role and mechanism of histone deacetylase SIRT1 in modulating fatty acid binding protein 4 (FABP4) stability and its impact on hepatic fibrosis and ferroptosis in non-alcoholic fatty liver disease (NAFLD).
methodsA murine NAFLD fibrosis model was induced by a Western diet combined with CCl4 injection. Mice received adenoviruses carrying oe-SIRT1 or sh-FABP4 three days before modeling. In vitro, NCTC 1469 hepatocytes were exposed to palmitic acid (PA) and transfected with oe-SIRT1 or oe-FABP4. Histopathology was assessed by HE, Masson, and Sirius red staining, and α-SMA by immunohistochemistry. Biochemical assays and molecular analyses measured liver injury markers, ferroptosis-related proteins, oxidative stress indices, and SIRT1/FABP4 expression. Cell viability, death, and lipid deposition were evaluated by CCK-8, LDH release, and Oil Red O staining. Co-IP and CHX chase assays examined SIRT1–FABP4 interaction, acetylation, and protein stability.
resultsNAFLD mice showed decreased SIRT1 and increased FABP4, with lipid degeneration, collagen deposition, α-SMA upregulation, and aggravated ferroptosis. Either SIRT1 overexpression or FABP4 knockdown alleviated inflammation, fibrosis, and ferroptosis in vivo. In PA-treated hepatocytes, cell viability declined, LDH release and lipid deposition increased, AST/ALT rose, ferroptosis intensified, SIRT1 was suppressed, and FABP4 was upregulated. Enhancing SIRT1 reduced FABP4 expression, attenuated lipid accumulation, and limited ferroptosis. Mechanistically, SIRT1 interacted with FABP4 to decrease its acetylation, thereby lowering FABP4 stability. FABP4 overexpression partially reversed the protective effect of SIRT1, promoting ferroptosis and lipid deposition.
conclusionSIRT1 reduces FABP4 acetylation and stability, thereby suppressing ferroptosis and hepatic fibrosis in NAFLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.